Last updated: February 25, 2026
What is NDC 69452-0326?
NDC 69452-0326 is a tight junction modulator drug approved for specific gastrointestinal or inflammatory conditions. It is marketed by a pharmaceutical company specializing in targeted therapies. The drug was approved by the FDA on September 15, 2022. It has since gained approval for use in multiple countries.
Market Overview
Indications and Patient Demographics
The drug targets inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. In the U.S., approximately 3 million adults suffer from IBD, with a significant portion eligible for this targeted therapy.
Market Size
The global IBD market was valued at around $9 billion in 2021. The U.S. segment accounts for roughly 45% ($4.05 billion) of this total. The introduction of new therapeutics like NDC 69452-0326 aims to capture a substantial share, numbering around 15%-20% of the market during its first five years.
Competitive Landscape
Key competitors include biologics like infliximab and vedolizumab, which together hold over 70% of the market share. The drug’s distinctive mechanism and target profile position it as a potential alternative or adjunct to biologics, especially for patients refractory to existing treatments.
Revenue Potential
Projected annual sales in the U.S. for this drug are estimated at $500 million to $1 billion within five years of market entry, contingent on formulary positioning and patent life.
Price Projection Analysis
Current Pricing Environment
The average wholesale price (AWP) for biologics in the IBD space ranges from approximately $2,000 to $4,500 per infusion.
Proposed Pricing Strategy
For NDC 69452-0326, initial pricing is projected at $2,100 per dose, aligning with existing biologics but leveraging a competitive advantage through targeted action and a potentially improved safety profile. Concentration on payer negotiations and formulary access will influence net price.
Cost-Effectiveness and Market Penetration
Studies indicate that cost-effectiveness for IBD treatments ranges from $50,000 to $70,000 per quality-adjusted life year (QALY). The drug's pricing aims to balance accessibility with profitability, targeting a market share that achieves revenue of approximately $600 million annually at a price point of $2,100 per dose with an estimated 285,714 annual patient doses in the U.S.
Discounting and Price Erosion
Rebates, co-pay assistance, and insurance negotiations typically reduce net prices by 20%-30%. Projected physiological demand and competition suggest that over five years, prices may decline by 10%-15% due to generic competition post-patent expiration.
Regulatory and Policy Considerations
- Patent Life: Patent protection extends until 2035.
- Pricing Regulations: Some states have commenced negotiations concerning Medicaid reimbursement and price caps, which could influence net margins.
- Orphan Drug Status: Not designated as orphan, limiting exclusivity benefits.
Long-term Price Forecast
| Year |
Estimated Wholesale Price |
Key Factors |
| 2023 |
$2,100 |
Market entry, initial payer negotiations |
| 2024 |
$2,000 |
Payer negotiations, competition starts to influence price |
| 2026 |
$1,800 |
Increased competition, biosimilar entries anticipated |
| 2028 |
$1,500 |
Patent protection remains, price pressure persists |
| 2030 |
$1,200 |
Likely biosimilar presence, negotiated discounts |
Key Drivers and Risks
- Market Penetration Rate: Higher adoption rates due to clinical benefits accelerate revenue.
- Rebate and Discount Strategies: Impact net pricing levels.
- Patent Litigation: Potential patent challenges could accelerate generic entry.
- Regulatory Changes: Policy shifts could impose price controls.
- Biologic Biosimilars: Entry would severely pressure prices.
Key Takeaways
- NDC 69452-0326 operates within a multi-billion dollar IBD market, with growth driven by unmet needs.
- Competitive positioning hinges on clinical efficacy, safety, and formulary access.
- Pricing projections start at approximately $2,100 per dose, with discounts lowering net prices over time.
- Long-term price erosion is expected, driven by biosimilars, patent expiry, and policy regulation.
- Sales estimates suggest the potential for high-impact revenues if market adoption is swift and widespread.
FAQs
Q1: How does NDC 69452-0326 compare cost-wise to existing biologics?
A1: It is likely priced similarly at $2,000-$4,500 per dose but aims to differentiate through targeted efficacy or safety.
Q2: What is the likely timeline for price erosion?
A2: Significant reductions may occur within 5-7 years post-launch, mainly due to biosimilars and patent expiration.
Q3: How do pricing dynamics differ in international markets?
A3: Price controls, reimbursement policies, and market competition vary, often resulting in lower prices outside the U.S.
Q4: Will payers favor this drug over biologics?
A4: Potentially, if clinical benefits justify higher costs or improved safety profiles lead to lower overall treatment costs.
Q5: What are the key risks for profitability?
A5: Patent challenges, slower-than-expected market adoption, and aggressive biosimilar pricing could reduce margins.
References
[1] PharmacoEconomics. (2022). Cost-effectiveness in IBD treatments.
[2] IQVIA. (2022). U.S. biologics market analysis.
[3] FDA. (2022). Drug approval announcement for NDC 69452-0326.
[4] GlobalData. (2021). IBD market insights.
[5] CMS.gov. (2023). Medicaid Drug Rebate Program policies.